Lucianò, Roberta

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 741

Il-23 secreted by myeloid cells drives castration-resistant prostate cancer

Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature

Prostate Cancer Treatment and ResearchImmune cells in cancer

Cited by 394

Bimodal CD40/Fas-Dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression

Cortesi, F., Delfanti, G., Grilli, A., Calcinotto, A., Gorini, F., Pucci, F., Lucianò, R., Grioni, M., Recchia, A., Benigni, F., et al. (2018) · Cell Reports

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 100

Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer

Pederzoli, F., Riba, M., Venegoni, C., Marandino, L., Bandini, M., Alchera, E., Locatelli, I., Raggi, D., Giannatempo, P., Provero, P., et al. (2024) · European Urology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 33